Skip to main content
. 2018 Apr 24;15(6):9725–9734. doi: 10.3892/ol.2018.8560

Figure 3.

Figure 3.

PFS and OS of patients with lymphoma treated with or without Rituximab based on CHOP. (A) The difference between patients treated with RCHOP (n=23) and CHOP (n=59) was statistically significant in PFS (P<0.001). (B) The difference between patients treated with RCHOP (n=23) and CHOP (n=59) was statistically significant in OS (P=0.003). PFS, progression free survival; OS, overall survival; CHOP, cyclophosphamide, vincristine, doxorubicin and prednisone; R, Rituximab; HR, hazard ratio; CI, confidence interval.